Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.

Mills CC, Kolb EA, Sampson VB.

Cancer Res. 2018 Jan 15;78(2):320-325. doi: 10.1158/0008-5472.CAN-17-2782. Epub 2018 Jan 8. Review.

PMID:
29311160
2.

Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.

Mills CC, Kolb EA, Sampson VB.

Cancer Res. 2017 Dec 1;77(23):6489-6498. doi: 10.1158/0008-5472.CAN-17-2066. Epub 2017 Nov 2. Review.

PMID:
29097609
3.

The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/╬▓III-Tubulin Axis.

Vetter NS, Kolb EA, Mills CC, Sampson VB.

Mol Cancer Res. 2017 Jul;15(7):953-964. doi: 10.1158/1541-7786.MCR-16-0372. Epub 2017 Mar 8.

4.

Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.

Sampson VB, Vetter NS, Zhang W, Patil PU, Mason RW, George E, Gorlick R, Kolb EA.

Oncotarget. 2016 Dec 27;7(52):86594-86607. doi: 10.18632/oncotarget.13358.

5.

Simulating the slow to fast switch in cytochrome c oxidase catalysis by introducing a loop flip near the enzyme's cytochrome c (substrate) binding site.

Alleyne T, Ignacio DN, Sampson VB, Ashe D, Wilson M.

Biotechnol Appl Biochem. 2017 Sep;64(5):677-685. doi: 10.1002/bab.1526. Epub 2017 Jun 7.

PMID:
27489224
6.

Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.

Sampson VB, Vetter NS, Kamara DF, Collier AB, Gresh RC, Kolb EA.

PLoS One. 2015 Nov 16;10(11):e0142704. doi: 10.1371/journal.pone.0142704. eCollection 2015.

7.

MicroRNAs and Potential Targets in Osteosarcoma: Review.

Sampson VB, Yoo S, Kumar A, Vetter NS, Kolb EA.

Front Pediatr. 2015 Aug 24;3:69. doi: 10.3389/fped.2015.00069. eCollection 2015. Review.

8.

Wilms' tumor protein induces an epithelial-mesenchymal hybrid differentiation state in clear cell renal cell carcinoma.

Sampson VB, David JM, Puig I, Patil PU, de Herreros AG, Thomas GV, Rajasekaran AK.

PLoS One. 2014 Jul 15;9(7):e102041. doi: 10.1371/journal.pone.0102041. eCollection 2014.

9.

Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.

Sampson VB, Kamara DF, Kolb EA.

Expert Opin Drug Discov. 2013 Oct;8(10):1181-9. doi: 10.1517/17460441.2013.817988. Epub 2013 Jul 12. Review.

10.

A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.

Sampson VB, Gorlick R, Kamara D, Anders Kolb E.

Front Oncol. 2013 May 31;3:132. doi: 10.3389/fonc.2013.00132. eCollection 2013.

11.

Na,K-ATPase is a target of cigarette smoke and reduced expression predicts poor patient outcome of smokers with lung cancer.

Huynh TP, Mah V, Sampson VB, Chia D, Fishbein MC, Horvath S, Alavi M, Wu DC, Harper J, Sarafian T, Dubinett SM, Langhans SA, Goodglick L, Rajasekaran AK.

Am J Physiol Lung Cell Mol Physiol. 2012 Jun 1;302(11):L1150-8. doi: 10.1152/ajplung.00384.2010. Epub 2012 Feb 17.

12.

Early electron transfer in cytochrome c oxidase occurs by a chymotrypsin type relay.

Alleyne T, Sampson VB.

West Indian Med J. 2009 Dec;58(6):499-505.

PMID:
20583674
13.

Probing the specifics of substrate binding for cytochrome c oxidase: a computer assisted approach.

Sampson VB, Alleyne T, Ashe D.

West Indian Med J. 2009 Jan;58(1):54-60.

PMID:
19565999
14.

Expression of Na,K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin.

Tummala R, Wolle D, Barwe SP, Sampson VB, Rajasekaran AK, Pendyala L.

Cancer Chemother Pharmacol. 2009 Nov;64(6):1187-94. doi: 10.1007/s00280-009-0985-x. Epub 2009 Mar 26.

15.

Failure of immunosuppressive drug levels to predict T-cell reactivity in pediatric transplant patients.

Sampson VB, Dunn SP, Rymeski B, Malatack J, Rong NH, Flynn L, Krueger LJ.

J Pediatr Surg. 2008 Jun;43(6):1134-41. doi: 10.1016/j.jpedsurg.2008.02.044.

PMID:
18558196
16.

MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.

Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ.

Cancer Res. 2007 Oct 15;67(20):9762-70.

Supplemental Content

Loading ...
Support Center